UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Gli promotes tumor progression and metastasis through regulating EMT in non–small-cell lung cancer

Annals of oncology, 2018-09, Vol.29, p.vi24-vi25

2018

Volltextzugriff (PDF)

GNMT negatively regulates MAPK pathway and suppresses the growth and metastasis of hepatocellular cancer cells

Annals of oncology, 2018-09, Vol.29, p.vi36-vi36

2018

Volltextzugriff (PDF)

Short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR): A planned interim analysis

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii167

2018

Volltextzugriff (PDF)

PD-L1 expression affect the efficacy of pemetrexed maintenance therapy in real-world patients with advanced non-squamous NSCLC

Annals of oncology, 2019-04, Vol.30, p.ii60-ii60

2019

Volltextzugriff (PDF)

31P The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer

Annals of oncology, 2020-10, Vol.31, p.S1226-S1226

2020

Volltextzugriff (PDF)

Osimertinib in advanced or metastatic non-small cell lung cancer patients with EGFR T790M mutation after treatment with EGFR-TKI: Interim analysis of China cohort from the single-arm, open-label, international, multi-center real-world ASTRIS study

Annals of oncology, 2018-11, Vol.29, p.ix158-ix158

2018

Volltextzugriff (PDF)

72PGli promotes tumor progression and metastasis through regulating EMT in non-small-cell lung cancer

Annals of oncology, 2018-09, Vol.29 (suppl_6)

2018

Volltextzugriff (PDF)

369P The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer

Annals of oncology, 2020-11, Vol.31, p.S1383-S1383

2020

Volltextzugriff (PDF)

Breast conservation therapy for stage I or stage II breast cancer: a meta-analysis of randomized controlled trials

Annals of oncology, 2008-06, Vol.19 (6), p.1039-1044

2008

Volltextzugriff (PDF)

115PGNMT negatively regulates MAPK pathway and suppresses the growth and metastasis of hepatocellular cancer cells

Annals of oncology, 2018-09, Vol.29 (suppl_6)

2018

Volltextzugriff (PDF)

26P Genome-wide copy number variation of circulating cell-free DNA as a biomarker in head and neck cancer patients treated with immunotherapy

Annals of oncology, 2021-12, Vol.32, p.S1384

2021

Volltextzugriff (PDF)

860P Pembrolizumab in combination with low-dose cisplatin/5-fluorouracil for neoadjuvant chemoimmunotherapy of locally advanced head and neck squamous cell carcinoma: A single-arm clinical trial

Annals of oncology, 2024-09, Vol.35, p.S620-S620

2024

Volltextzugriff (PDF)

378P Updated data on real-world efficacy and safety of inetetamab-based therapy in HER2-positive metastatic breast cancer patients with prior exposure to trastuzumab

Annals of oncology, 2024-09, Vol.35, p.S377-S377

2024

Volltextzugriff (PDF)

62P PD-1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in patients with advanced non-squamous non-small cell lung cancer: A pooled analysis of three randomized trials

Annals of oncology, 2021-12, Vol.32, p.S1399

2021

Volltextzugriff (PDF)

434P Nomogram to predict occult N2 lymph nodes metastases in patients with squamous non-small cell lung cancer

Annals of oncology, 2015-12, Vol.26, p.ix125-ix125

2015

Volltextzugriff (PDF)

219P Clinical effectiveness of tislelizumab plus TKI as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): A real-world study

Annals of oncology, 2023-11, Vol.34, p.S1560-S1561

2023

Volltextzugriff (PDF)

215P Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)

Annals of oncology, 2023-11, Vol.34, p.S1559-S1560

2023

Volltextzugriff (PDF)

1681P A retrospective real-world study for nimotuzumab plus postoperative adjuvant chemotherapy for resectable pancreatic cancer

Annals of oncology, 2023-10, Vol.34, p.S921-S921

2023

Volltextzugriff (PDF)

30P A phase I, dose-escalation and dose-expansion study of SY-3505: A third-generation ALK TKI in Chinese ALK-positive advanced non-small cell lung cancer

Annals of oncology, 2022-04, Vol.33, p.S45

2022

Volltextzugriff (PDF)

LBA5 Capivasertib (C) + fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2– advanced breast cancer (ABC): Phase III CAPItello-291 trial Chinese cohort

Annals of oncology, 2023-11, Vol.34, p.S1485-S1486

2023

Volltextzugriff (PDF)

1369P EGFR T790M ctDNA abundance and TP53 co-mutation by next generation sequencing predicted clinical outcomes of osimertinib in non-small cell lung cancer patients from a real-world study

Annals of oncology, 2020-09, Vol.31, p.S874-S874

2020

Volltextzugriff (PDF)

249P The efficacy and safety of short-course radiotherapy followed by sequential chemotherapy and cadonilimab for locally advanced rectal cancer: The preliminary findings of prospective, multicenter phase II trial

Annals of oncology, 2024-06, Vol.35, p.S107-S107

2024

Volltextzugriff (PDF)

1973P Antitumor activity of olverembatinib (HQP1351) in patients (pts) with TKI-resistant succinate dehydrogenase- (SDH-) deficient gastrointestinal stromal tumor (GIST)

Annals of oncology, 2023-10, Vol.34, p.S1053-S1054

2023

Volltextzugriff (PDF)

562P First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort

Annals of oncology, 2023-11, Vol.34, p.S1689

2023

Volltextzugriff (PDF)

388P Capmatinib in Chinese adults with EGFR wt, ALK rearrangement negative (ALK-R−), MET exon 14 skipping mutation (METex14), advanced NSCLC: Results from the phase II GEOMETRY-C study

Annals of oncology, 2022-11, Vol.33, p.S1593

2022

Volltextzugriff (PDF)

1 – 25 von 341

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieApplied Physics Letters

Zeitschrift / SerieAnnals Of Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(341)
Mit Volltextzugriff
(341)

Publikationsform

Artikel
(341)

Sprache

Englisch
(341)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(39)
Oncology
(39)
Science & Technology
(39)
Humans
(34)
Female
(23)
Aged
(16)
Middle Aged
(16)
Male
(15)
Adult
(14)
Antineoplastic Agents
(10)
Biological And Medical Sciences
(10)
Medical Sciences
(10)
Pharmacology. Drug Treatments
(10)
Aged, 80 And Over
(9)
Disease-Free Survival
(8)
Original
(8)
Treatment Outcome
(8)
Breast Neoplasms - Drug Therapy
(7)
Young Adult
(7)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(6)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB-FREE-00999 freely available EZB journals
(341)
Journals@Ovid
(341)
MEDLINE
(34)
IngentaConnect Journals
(4)

Zeitschrift / Serie

Annals Of Oncology : Official Journal Of The European Society For Medical Oncology
(1)

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(17)

Menü

Weitere Dienste

Einstellungen

Gli promotes tumor progression and metastasis through regulating EMT in non–small-cell lung cancer

GNMT negatively regulates MAPK pathway and suppresses the growth and metastasis of hepatocellular cancer cells

Short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR): A planned interim analysis

PD-L1 expression affect the efficacy of pemetrexed maintenance therapy in real-world patients with advanced non-squamous NSCLC

31P The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer

Osimertinib in advanced or metastatic non-small cell lung cancer patients with EGFR T790M mutation after treatment with EGFR-TKI: Interim analysis of China cohort from the single-arm, open-label, international, multi-center real-world ASTRIS study

72PGli promotes tumor progression and metastasis through regulating EMT in non-small-cell lung cancer

369P The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer

Breast conservation therapy for stage I or stage II breast cancer: a meta-analysis of randomized controlled trials

115PGNMT negatively regulates MAPK pathway and suppresses the growth and metastasis of hepatocellular cancer cells

26P Genome-wide copy number variation of circulating cell-free DNA as a biomarker in head and neck cancer patients treated with immunotherapy

860P Pembrolizumab in combination with low-dose cisplatin/5-fluorouracil for neoadjuvant chemoimmunotherapy of locally advanced head and neck squamous cell carcinoma: A single-arm clinical trial

378P Updated data on real-world efficacy and safety of inetetamab-based therapy in HER2-positive metastatic breast cancer patients with prior exposure to trastuzumab

62P PD-1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in patients with advanced non-squamous non-small cell lung cancer: A pooled analysis of three randomized trials

434P Nomogram to predict occult N2 lymph nodes metastases in patients with squamous non-small cell lung cancer

219P Clinical effectiveness of tislelizumab plus TKI as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): A real-world study

215P Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)

1681P A retrospective real-world study for nimotuzumab plus postoperative adjuvant chemotherapy for resectable pancreatic cancer

30P A phase I, dose-escalation and dose-expansion study of SY-3505: A third-generation ALK TKI in Chinese ALK-positive advanced non-small cell lung cancer

LBA5 Capivasertib (C) + fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2– advanced breast cancer (ABC): Phase III CAPItello-291 trial Chinese cohort

1369P EGFR T790M ctDNA abundance and TP53 co-mutation by next generation sequencing predicted clinical outcomes of osimertinib in non-small cell lung cancer patients from a real-world study

249P The efficacy and safety of short-course radiotherapy followed by sequential chemotherapy and cadonilimab for locally advanced rectal cancer: The preliminary findings of prospective, multicenter phase II trial

1973P Antitumor activity of olverembatinib (HQP1351) in patients (pts) with TKI-resistant succinate dehydrogenase- (SDH-) deficient gastrointestinal stromal tumor (GIST)

562P First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort

388P Capmatinib in Chinese adults with EGFR wt, ALK rearrangement negative (ALK-R−), MET exon 14 skipping mutation (METex14), advanced NSCLC: Results from the phase II GEOMETRY-C study

Aktive Filter

Suchergebnisse filtern